Imaging biomarkers in drug development: An overview of opportunities and open issues

Journal of Proteome Research

Volumn 4, Issue 4, 2005, Pages 1134-1137

  Chandra, Sudeep ^a   Muir, Craig ^a   Silva, Matt ^a   Cari, Steven ^a,b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

COMPUTER ASSISTED TOMOGRAPHY; DRUG INDUSTRY; DRUG RESEARCH; GENE EXPRESSION PROFILING; IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; DRUG DESIGN; HUMANS; MICE; NEOPLASMS; PROGNOSIS;

EID: 23944447110     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0500915     Document Type: Review

References (41)

1. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of Innovation: new estimates of drug development costs, J. Health Econ. 2003, 22, 151-185.
2. Walker, M. J. A. Functional pharmacology: the drug discovery bottlenecks? Drug Targets 2004, 3, 5.
3. DiMasi, J. A. The value of improving the productivity of the drug development process, Pharmacoeconomics 2002, 20(Suppl 3), 1-10.
4. Sinskey, A.; Finkelstein, S.; Cooper, S. PharmaGenomics 2004, March/April.
5. Chandra, S.; Clark, L. V.; Coatney, R. W.; Phan, L.; Sarkar, S. K.; Ohlstein, E. H. Application of serial in vivo magnetic resonance imaging to evaluate the efficacy of endothelin receptor antagonist SB 217242 in the rat carotid artery model of neointima formation. Circulation 1998, 97, 2252-2258.
6. Beckman, N.; Falk, R.; Zurbrugg, S.; Dawson, J.; Engelhardt, P. Macrophage infiltration into the rat knee detected by MRI in a model of antigen-induced arthritis. Magn. Reson. Med. 2003, 49, 1047-1055.
7. Beckman, N.; Tigani, B.; Mazzoni, L.; Fozard, J. R. Techniques: magnetic Resonance imaging of the lung provides potential for noninvasive pre-clinical evaluation of drugs, TIPS 2003, 24, 10.
8. Middleton, H.; Black, R. D.; Saam, B.; Gates, G. D.; Gofer, G. P.; Guether, R.; Happer, W.; Hedlund, L. W.; Johnson, G. A. Magnetic Resonance Imaging with hyperpolarized 3He gas. Magn. Reson. Med. 1995, 33, 271-275.
9. Samee, S.; Altes, T.; Powers, P.; de Lange, E. E.; Knight-Scotts, T.; Rakes, G.; Mugler, J. P.; Ciambotti, J. M.; Alford, B. A.; Brookeman, J. R.; Platts-Mills, T. A. Imaging the lungs in asthmatic patient-susing hyperpolarized Helium-3 magnetic resonance assessment of response to methcholine exercise challenge. J. Allergy Clin. Immun. 2003, 111, 1205-1211.
10. Beckman, N.; Mueggler, T.; Allegrini, P. R.; Laurent, D.; Rudin, M. From Anatomy to the target: contribution of magnetic resonance imaging to pre-clinical pharmaceutical research. Anat. Rec. 2001, 265, 85-100.
11. Rudin, M.; Beckman, N.; Porszasz, R.; Reese, T.; Bochelen, D.; Sauter, A. In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives, NMR Biomed. 1999, 12, 69-97.
12. Cherry, S. R. Fundamentals of Positron Emission Tomography and applications in pre-clinical drug development, J. Clin. Pharmacol. 2001, 41, 482-491.
13. Blankenberg, F. G.; et al. Tumor Imaging Using a Standardized Radiolabeled Adapter Protein Docked to Vascular Endothelial Growth Factor, J. Nucl. Med. 2004, 45, 1373-1380.
14. Borah, B.; et al. Three-dimensional microimaging, finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. Anat. Rec. 2001, 265, 101-110.
15. Suva, M.; Wen, S.; Siebert, E.; Shi, J.; Myers, M.; Worland, P.; Henry, M.; Chandra, S. Diffusion-weighted Magnetic Resonance Imaging Characterization of Antitumor Activity of MLN 2704 in a bone metastatic cancer model. Proc. Int. Soc Magn. Reson. Med. 2004, 12, 2510.
16. Weber et al. Positron Emission Tomography in nonsmall cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J. Clin. Oncol. 2003, 21, 2651-2657.
17. Gross, S.; Worms, P. D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 2005, 7, 5-15.
18. Weissleder, R.; Mahmood, U. Molecular Imaging. Radiology 2001, 219, 316-333.
19. Suva, M.; Chandra, S. Insights on Use of Magnetic Resonance Imaging for Testing Efficacy of Drug Candidates In Magnetic Resonance Imaging; Principles and Practice; Prasad, P. V. Ed.; 2005.
20. Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer, 2003, 2, 11-18.
21. Rudin, M.; Weisleder, R. Molecular Imaging in Drug Discovery and Development. Nat. Rev. Drug Discov. 2003, 2, 123-131.
22. Weisleder, R.; Moore, A.; Mahmood, U.; Bhorade, R.; Benveniste, H.; Chiocca, E. A.; Basilion, J. P. In vivo Magnetic Resonance Imaging of Transegene Expression. Nat. Med. 2000, 63, 351-354.
23. Pomper, M. G. Can small animal Imaging accelerate drug development? J. Cell Biochem. 2002, Suppl. 39, 211-230.
24. Rao, A. B.; et al. Methylpredinolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002, 59, 688-694.
25. Neeman, M.; Dafni, H. Structural, functional and molecular MR imaging of the microvasculature. Annu. Rev. Biomed Enggr. 2003, 5, 29-56.
26. Morgan, B.; et al. Dynamic Contrast-enhanced Magnetic Resonance Imaging as a Biomarker for the pharmacological response of PTK 787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases in patients with advanced colorectal cancer and liver metastases: results from two phase 1 studies. J. Clin Oncol. 2003, 21, 3955-3964.
27. Miles, K. A. Functional computed tomography in Oncology. Eur. J. Cancer 2002, 38, 2079-2084.
28. Davis, D. W.; et al. Surrogate markers in antiangiogenesis Clinical trials. Br. J. Cancer 2003, 89, 8-14.
29. Fishman et al., Pharmacokinetics of 18F-labeled flucazonole in healthy human subjects by positron emission tomography. Antimicrob. Agents Chemother. 1993, 37, 1270-1277.
30. Kalff, V.; Hicks, J.; MacManus, M. P.; Binns, D. S.; McKenzie, A. F.; Ware, R. E.; Hogg, A.; Ball, D. J. Clin. Onc. 2001, 19(1), 111-118.
31. Schelling, M.; et al. Positron Emission tomogrpahy using 18FDG for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol. 2000, 18, 1689-1695.
32. Weber, W.; et al. Prediction of response to pre-operative chemotherapy in adenocarcinoma of the esophagogastric junction by metabolic imaging. J. Clin. Oncol. 2001, 19, 3058-65.
33. Bathon, J. M.; et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 2000, 343, 1586-1593.
34. Stroobants, S.; et al. 18FDG PET for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer 2003, 39, 2012-2020.
35. Pien, H. H.; Fischman, A. J.; Thrall, H. J.; Sorensen, A. G. Using imaging Biomarkers to accelerate drug development and clinical trials. Drug Discov. Today 2005, 10, 4.
36. Henry, M. H.; Wen, S.; Silva, M. D.; Chandra, S.; Milton, M.; Worland, P. A PSMA-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004, 64, 7995-8001.
37. Gilles, R. J.; Bhujwalla, Z. M.; Evelhoch, J.; Garwood, M.; Neeman, M.; Robinson, S. P.; Sotak, C. H.; Vand der Sanden, B. Application of Magnetic Resonance in Model Systems: Tumor Biology and Physiology. Neoplasia 2000, 2, 139-151.
38. Silva, M. D.; Savinainen, A.; Kapadia, R.; Avitahl, N.; Mosher, R.; Anderson, K.; Jaffee, B.; Schopf, L.; Chandra, S. Quantitative microCT Imaging and Histopathological Signatures of Rheumatoid Arthritis in Rats. J. Mol. Imag. 2004, Dec.
39. Frank, R.; Hargreaves, R. Clinical biomarkers in Drug Discovery and Development. Nat. Rev. Drug Discov. 2003, 2, 566.
40. Critical Path opportunities: DIA-FDA workshop on Imaging, May 5, 6, 2005, Bethesda, USA.
41. The Gray Sheet; Imaging Technologies tagged for FDA drug development initiative, Feb 2, 2004.